INTRODUCTION
Non-melanoma skin cancers (NMSC) are the most common form of human skin cancer. The majority of NMSC are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), with an incidence of 1:4 in immunocompetent patients. 1 However, there is no compulsory registration of BCC in Brazil, and many studies have grouped BCC and SCC in their reports. 2 BCC has an estimated risk of 56 new cases per 100,000 men and 61 per 100,000 women. However, rates vary according to the region and the ethnic composition of the population. 3 There is a greater involvement of men than women (1.5-2:1), probably due to professional reasons, and the male gender is also associated with a higher number of tumors. 4, 5 BCC is responsible for 80%
of NMSC, being more frequent in patients aged <40 years, although mean age at first diagnosis is approximately 60 years. 6, 7 The most important constitutional risk factors for BCC de- Ethnic, cultural and occupational aspects should also interfere with the epidemiological patterns of BCC in different countries. 10 Other risk factors include immunosuppression, exposure to arsenic, scars and hereditary diseases such as Gorlin-Goltz syndrome (basal cell nevus syndrome) and xeroderma pigmentosum. 10, 11 There are many histological subtypes, however a simplified division classifies BCC into three subtypes: superficial, nodular and infiltrative. 12 Abstract: Basal cell carcinoma is the most common cancer, presenting low mortality but high morbidity, and it has as risk factor exposure to sunlight, especially UVB spectrum. The most important constitutional risk factors for basal cell carcinoma development are clear phototypes (I and II, Fitzpatrick classification), family history of basal cell carcinoma (30-60%), freckles in childhood, eyes and light hair. The environmental risk factor better established is exposure to ultraviolet radiation. However, different solar exposure scenarios probably are independent risk factors for certain clinical and histological types, topographies and prognosis of this tumor, and focus of controversy among researchers. Studies confirm that changes in cellular genes Hedgehog signaling pathway are associated with the development of basal cell carcinoma. The cellular Hedgehog signaling pathway is activated in organogenesis, but is altered in various types of tumors. Keywords: Carcinoma, basal cell; Genetics; Hedgehog protein the face (30% on the nasal region) and cervical region. 17, 21 Trunk involvement occurs in 15-43% of cases. 22 Occurrence of BCC in areas less exposed to sun is of approximately 20% of cases. They are usually of greater diameter due to delayed diagnosis, and can present with worse prognosis, surgical morbidity and metastases. 23 Mean duration of the lesions, from onset to diagnosis, is 37.1 months for both sexes. 19 Cure rates exceed 90% with excisional surgical treatment, and BCC-specific mortality is less than 0.1%. The incidence of BCC metastases is rare and ranges from 0.0028% to 0.55%. 8, 10, 24 BCC was primarily described by Jacob in 1827, who named it ulcus rodens, and its current nomenclature was proposed by Krompecher in 1903. 25 There are no precursor lesions described for BCC, and the cells involved in their origin are controversial. 8, 10 There is Relation between cancer and Hh pathway activation has been examined from the report of germinal mutations of function loss in PTCH in patients with Gorlin syndrome (BCNS syndrome, Gorlin). 48 BCNS is an autosomal dominant disease characterized by multiple developmental abnormalities and predisposition to tumors, specifically BCC, medulloblastoma (MB), embryonal rhabdomyosarcoma, and meningioma. 49 Somatic mutations in PTCH were identified in 90% of sporadic BCCs, and function gain mutations in SMO were detected in BCCs. 50 In particular, recurrent mutations in SMO and functional studies have demonstrated that these mutations lead to aberrant activation of Hh signaling and promote tumor development. 51 Somatic mutations in PTCH have also been detected in other tumors, such as ovary and endometrium. 52 In addition to the SMO-dependent pathway, phosphatidylinositol-3-kinase (PI3K) also promotes Hh signaling in oncogenesis. S6-kinase 1 (S6K1) and atypical protein kinase C (aPKC), components that are downstream of PI3K, promote GLI-dependent transcription. S6K1 is also downstream of the target mammalian rapamycin pathway (mTOR) and has been found to be elevated in esophageal cancer resistant to SMO antagonists. 53 In addition, PI3K
may promote the activation of 3-phosphoinosinoside-dependent kinase 1 (PDK1), which promotes mTOR and activation of S6K1. S6K1
promotes GLI-dependent transcription by Gli1 phosphorylation, which prevents an interaction that allows GLI to enter the nucleus and activate target genes. An Hh target gene is aPKC that phosphorylates Gli1 at sites other than S6K1, activating Gli1 binding to DNA, which can generate positive feedback that amplifies GLI-dependent transcription in BCC. 53 The first well-studied therapy targeting the Hh pathway was cyclopamine, a steroidal alkaloid from the Veratum californicum plant, which acted directly on a Sonic Hh pathway, known as definer of cyclophopone phenotype in mice. 54 This established an important connection between cyclopamine and activation of the 
